Addison’s disease, more commonly known as adrenal insufficiency, is a rare hormonal disorder wherein the adrenal gland produces little cortisol and aldosterone hormone as compared to the amount required. The disease is highly life threatening, and is prevalent in both males and females of all ages. Few of the symptoms associated with the diseases include extreme fatigue, weight loss, salt craving, abdominal pains, and nausea. If not diagnosed at a pilot stage, Addison diseases can further lead to a more life threatening Addisonian crisis. The symptoms associated with the crisis include hyperpigmentation, lightheadedness, and severe gastrointestinal problems. As mentioned above, Addison’s diseases is caused due to severe damage done to adrenal glands. The gland consists of an inner and an outer layer, which are capable of producing corticosteroids and aldosterone respectively. Corticosteroids further include glucocorticoids, mineralocorticoids, and androgens. Addison’s disease treatment involves medication to correct unbalanced levels of hormone in the body. These medications involve hydrocortisone, prednisone & methylprednisolone, and fludrocortisone acetate.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the Addison’s disease treatment market.
Top Impacting Factors
- Rising incidents of Addison’s diseases around the globe coupled with growing demand for advanced therapeutics for quick, reliable, and sustainable treatment is anticipated to drive growth of the Addison’s disease treatment market.
- Growing awareness on Addison’s disease in emerging and underdeveloped economies coupled with inception of robust healthcare infrastructure and favorable reimbursement policies are expected to further anticipated to boost the growth of the Addison’s disease treatment.
- Drug misuse in farfetched regions of the globe hinders the market growth.
- Additionally, high costs associated with the Addison’s treatment medications pose extra burden on the distributions while channeling the products in underdeveloped economies with low economic muscle and less purchasing parity.
- Shift of healthcare infrastructure toward battling COVID-19 has led to product launch cancellations and delays in clinical trials. This is, thus, expected to decline the global market penetration of Addison’s disease treatment mechanisms in the coming years.
Key Market Trends
- North America is anticipated to showcase dominance in the Addison’s disease treatment market, owing to rising cases of the disease in the region coupled with growing demand for new age technologically integrated advanced therapeutic medications for quick and sustainable treatment.
- Research is being carried out on design and development of delayed release corticosteroids, which have shown greater efficiency when administered into the human body.
- Clinical trials are being conducted across North America on potential pumps implanted under skin for delivery of steroids in accurate doses.
- Recent study conducted at University of Bergen (UB) has brought into consideration direct relationship between genetic signals and the onset of the disease. The genes known as Autoimmune Regulators (AIRE) are responsible for removing self-reacting autoimmune cells. Absence of AIRE may compromise on removal of these self-reacting cells, which may further lead to Addison’s disease in the future.
Key Benefits of the Report
- This study presents the analytical depiction of the Addison’s disease treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the Addison’s disease treatment market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Addison ’s disease Treatment Report
- Which are the leading players active in the Addison’s disease treatment market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the Addison’s disease treatment market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is Addison’s disease treatment?
- What is the Addison’s disease treatment market prediction in the future?
- What are the current trends and predicted trends?
Addison’s Disease Treatment Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Route of Administration |
|
 By Diagnosis |
|
 By Treatment |
|
 By Region |
|
 By Distribution Channel |
|
 Key Market Players | Bristol-Myers Squibb Company, Eli Lilly and Company, Lupin, Bayer AG, Amgen Inc., Merck & Co. Inc, Biogen, Takeda Pharmaceutical Company Limited, Pfizer Inc., GlaxoSmithKline plc, Abbott, Novartis AG |
Loading Table Of Content...
